Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefited from first-line treatment with the targeted therapies encorafenib and cetuximab plus a mFOLFOX6 chemotherapy regimen, according to results from the PhaseIII BREAKWATER trial.
source https://www.sciencedaily.com/releases/2025/01/250125152749.htm
Every Microsoft Surface should have this tiny app that fixes a battery
headache
-
Microsoft still makes you dig through the Surface app to pause Smart
Charging, but a new third-party tool called Surface Charging Tray brings
those toggles...
1 day ago
Welcome to the 'The Fact Factory' friends. Its an interesting Hot Spot which brings to you amazing and little known facts from all over the world. So, sit back, take a tour around the world and enjoy the trivia.
No comments:
Post a Comment